21:40:54 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-19 Årsstämma 2024
2024-04-19 Ordinarie utdelning CLINE B 0.00 SEK
2024-02-23 Bokslutskommuniké 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-04-20 Ordinarie utdelning CLINE B 0.00 SEK
2023-04-19 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2023-02-17 Bokslutskommuniké 2022
2022-08-26 Kvartalsrapport 2022-Q2
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Ordinarie utdelning CLINE B 0.00 SEK
2022-04-20 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-08-27 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning CLINE B 0.00 SEK
2021-06-03 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-25 Kvartalsrapport 2020-Q2
2020-02-27 Ordinarie utdelning CLINE B 0.00 SEK
2020-02-26 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-05-08 Ordinarie utdelning CLINE B 0.00 SEK
2019-05-07 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-08-10 Kvartalsrapport 2018-Q2
2018-05-03 Ordinarie utdelning CLINE B 0.00 SEK
2018-05-02 Årsstämma 2018
2018-02-23 Bokslutskommuniké 2017
2017-08-11 Kvartalsrapport 2017-Q2
2017-03-21 Ordinarie utdelning CLINE B 0.00 SEK
2017-03-20 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-11-04 Kvartalsrapport 2016-Q3
2016-08-04 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning CLINE B 0.00 SEK
2016-05-03 Kvartalsrapport 2016-Q1
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Cline Scientific är verksamt inom bioteknik. Bolaget är specialiserat inom cancerdiagnostik och stamcellsterapier. Bolaget genomför utvecklingsprojekt via samarbeten med forskningsinstitutioner, där teknologin används i cellbaserade produkter och processer för att driva Life Science projekt till och genom den kliniska fasen. Bolaget har sitt huvudkontor i Göteborg och grundades under 2012.
2022-12-14 16:20:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTION. 

Cline Scientific AB's (publ) ("Cline" or the "Company") rights issue of shares, which was announced by press release on November 2, 2022, has now been registered with the Swedish Companies Registration Office.

The last day of trading in paid subscribed shares (BTA) on Nasdaq First North Growth Market will be on December 19, 2022 and stop day will be on December 21, 2022. The new shares are expected to be booked in each shareholder's VP account/depository on December 23, 2022.

For more information, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 703-585 088

About Cline Scientific

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline's unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 16:20 CET on 14 December 2022.

Important Information
The publication, release or distribution of this press release may be subject to restrictions in certain jurisdictions. Recipients of this press release in those jurisdictions where this press release has been published, disclosed or distributed should inform themselves of and observe any such restrictions. This press release does not constitute an offer of, or an invitation to acquire or subscribe for, any securities of Cline Scientific in any jurisdiction.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The information contained in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United Kingdom, the United States, Canada, Japan, Australia, Hong Kong, New Zealand, South Africa, South Korea or any other jurisdiction where such release, publication or distribution would be contrary to applicable law or regulation.

Within the European Economic Area, no securities are offered to the public in any country other than Sweden.

This press release contains certain forward-looking information that reflects the Company's current views on future events and financial and operational developments. Words such as "intends", "estimates", "expects", "may", "plans", "believes", "estimates" and other expressions which imply indications or predictions of future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is inherently subject to known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information is not a guarantee of future performance or development, and actual results may differ materially from those expressed in the forward-looking information.

Cline Scientific AB (publ)Phone: 031-387 55 55

Argongatan 2CEmail: info@clinescientific.com

431 53 MÖLNDAL Website: www.clinescientific.com